Compare Ishares Msci Italy ETF (EWI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ishares Msci Italy ETF trades at $56.06 (market cap $1.20B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Ishares Msci Italy ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Ishares Msci Italy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 55 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWI | MRVI | |
|---|---|---|
Market Cap | $1.20B | $972.90M |
Volume | 332,777 | 4,325,710 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $9.00 |
52-Week Low | $50.47 | $2.83 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.66 with a 0.87% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral with RSI levels suggesting potential oversold conditions. The ETF offers concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU-supported infrastructure investments.
The outlook remains cautious due to eurozone economic pressures and ECB tightening, but EWI provides strategic access to Italy's banking and infrastructure investment cycle. Key risks include eurozone business confidence declines and energy price volatility. Analyst sentiment is mixed with technical weakness offset by long-term structural opportunities in Italian markets.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
